The European Commission has approved Roche haemophilia A drug Hemlibra for patients without factor VIII inhibitors, expanding the use of the drug that is expected to drive sales as blockbus
AbbVie and Roche’s Venclexta is making headway as a second-line chronic lymphocytic leukaemia (CLL) treatment, and a new US filing could extend its use into the first-line setting.
Biogen has agreed to buy UK-based gene therapy biotech Nightstar, which focuses on using modified viruses as therapies for inherited retinal disorders, in a deal worth $800 million.